MS Pharma Launches MENA's First Biologics Manufacturing Hub in Saudi Arabia

On August 27, 2025, MS Pharma proudly announced the inauguration of the Middle East's first biologics manufacturing facility in Riyadh, Saudi Arabia. This innovative facility stands as a landmark achievement not only for MS Pharma but also for the biopharmaceutical landscape in the MENA region. Equipped with state-of-the-art technology and advanced capabilities, this facility represents a significant investment of USD 50 million aimed at bolstering local production and creating strategic partnerships.

Meeting International Standards

The facility has received Good Manufacturing Practice (GMP) certification from the Saudi Food and Drug Authority (SFDA) and complies with the stringent regulations set by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Specializing in the production of monoclonal antibodies and complex peptides, the plant is set to cater to the increasing global demand for biologic treatments, which have gained momentum in recent years due to their effectiveness in treating a range of serious health conditions.

One of the noteworthy features of this facility is its in-house bioanalytical testing laboratories. This development eliminates the dependency on overseas testing and considerably speeds up the time it takes for critical treatments to reach the market.

Strategic Partnerships

MS Pharma's new biologics hub is not just a manufacturing facility but a strategic platform that enables the company to engage global pharmaceutical partners. By providing localized and contract manufacturing solutions, MS Pharma positions itself as an attractive option for international firms looking to access the Saudi Arabian and broader MENA markets. As the demand for biopharmaceuticals continues to grow, this facility offers an efficient pathway for market entry, ensuring that partners can produce high-quality biologics tailored specifically to regional healthcare needs.

Aligning with National Goals

Saudi Arabia's Vision 2030 aims to enhance local industry and reduce reliance on imports. By establishing this biologics hub, MS Pharma is aligned with national goals to foster high-skilled employment and promote technology transfer within the region. This initiative not only strengthens local supply chains but also contributes positively to the overall economy by creating new job opportunities.

Ghiath Sukhtian, Chairman of MS Pharma, emphasized the importance of this launch, stating, "This milestone reshapes the MENA biopharmaceutical landscape. We are committed to developing a regional biologics platform that meets global healthcare demands and enables the delivery of high-value medicines in partnership with international players."

Kalle Känd, CEO of MS Pharma, added that the facility is a crucial step towards enhancing the company’s capabilities and expanding its global outreach. It stands as a testament to MS Pharma’s commitment to quality and innovation in the biopharmaceutical sector.

About MS Pharma

Founded in 1989 in Amman, Jordan, MS Pharma is a leading multinational pharmaceutical company dedicated to improving healthcare access in the Middle East, Africa, and beyond. With over 2,000 employees across twelve countries and five manufacturing plants strategically located in Jordan, Algeria, and now Saudi Arabia, the company continues to expand its portfolio with generics, complex injectables, and biosimilars for various therapeutic areas, including oncology, cardiovascular health, and central nervous system disorders.

In conclusion, MS Pharma’s new biologics manufacturing hub marks a transformative moment for the pharmaceutical industry in the region. It sets the stage for enhanced healthcare solutions while fostering a robust economic environment bolstered by strong local partnerships and innovative manufacturing practices.